Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332938 | 0.90 | KDM4E (0.61) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3331612 | 0.88 | KDM4E (0.57) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3334723 | 0.86 | KDM4E (0.60) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3334279 | 0.86 | KDM4E (0.63) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3334378 | 0.86 | KDM4E (0.56) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3335980 | 0.85 | KDM4E (0.59) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3329378 | 0.85 | KDM4E (0.63) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3334079 | 0.85 | KDM4E (0.58) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3338157 | 0.85 | KDM4E (0.58) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 | |
| SCHEMBL3334764 | 0.84 | KDM4E (0.54) | KDM4EHPGDHSD17B10NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | claimed |
| CN-101679261-A | Piperazine and piperidine mglur5 potentiators | ASTRAZENECA AB | 2010-03-24 | — | — | CN | claimed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| CN-101679261-A | Piperazine and piperidine mglur5 potentiators | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | KDM4E 3322/4885HPGD 2221/4885HSD17B10 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.